Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy
Phase of Trial: Phase IV
Latest Information Update: 05 Jul 2016
At a glance
- Drugs Bupivacaine (Primary)
- Indications Anaesthesia; Postoperative pain
- Focus Pharmacokinetics
- Sponsors Pacira Pharmaceuticals
- 20 May 2016 Dose of the EXPAREL is changed from 266 mg (20 mL) to 133 mg (10 mL).
- 08 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 19 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.